• Advanced the 12CQ quantum project 1HCY26 goal: development and demonstration of a qubit
• Began contract work with Paragraf to improve the Biochip gFETs ability to accurately test blood samples
• Fabricated a silicon chip that integrates the Biochip gFET with electrical readout circuitry

Archer Materials Limited, a semiconductor company advancing the quantum computing and medical diagnostics industries, provided its Quarterly Activities Report and Appendix 4C for the quarter ended 30 June 2025. The company made progress in its key technology development and commercialisation activities. In the quantum technologies segment, the 12CQ project bolstered the development of its carbon-based qubit by extending its work with Queen Mary University of London (QMUL) for a further six months, aiming to showcase significant technical advancements in qubit development. The company also continued its work on the TMR sensor program to identify a commercially attractive application. In the Biochip segment, Archer advanced the testing of chronic kidney disease (CKD) by signing an agreement with Paragraf Limited to undergo a contract of work on the Biochip to test blood potassium using a graphene field effect transistor (gFET). The Biochip team also created a silicon chip that combines the company's gFET sensors with electrical readout circuitry, a precursor to inserting the Biochip into a cartridge for a hand-held digital device. Archer also formed a new advisory committee comprising experienced industry experts to provide advice on the company's strategy, research, development, and commercialisation.